The natural solution for refractive change
Our tissue addition technology uses precisely-shaped human corneal allografts to create an essentially permanent, living contact lens.
Human Corneal Allografts
Allotex Inc. is an ophthalmic biologics and device company developing new therapeutic solutions for the treatment of presbyopia, hyperopia, and myopia. The therapy is accomplished through tissue addition technology that uses precisely-shaped human corneal allografts to create what is essentially a permanent, living contact lens or lens insert.
Allotex is a start-up company led by Drs. David Muller and Michael Mrochen.
Allotex Tissue Addition
Allotex corneal allografts are an evolution of Barraquer’s pioneering work, based on more than 50 years of clinical and laboratory studies.
Placing an onlay under the epithelium is the least invasive of all refractive procedures—and it's only possible with allograft tissue.
Allotex corneal allografts have the potential to treat presbyopia, hyperopia, myopia and astigmatism.
Unlike synthetic inlays, Allotex corneal allografts can be made in any shape, diameter and thickness.
Unlike synthetic inlays, Allotex corneal allografts can be placed on top of or just under Bowman’s—there is no need to place them deep in the cornea.
A survey of potential refractive patients indicates that patients would prefer human allograft inlays over synthetic inlays by a margin of eight to one.
It's everything we've learned since Barraquer
The corneal correction of refractive error with Allotex allograft tissue combines everything we've learned through decades of corneal inlay research and technology development with the pristine biocompatibility of human collagen. I'm very excited that I'll be able to deliver Allotex technology to my patients.